louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06067282: Effect of Microteaching Training on the Teaching Skills Level of University Students
Official title: Effect of 12-week Microteaching Training on the Teaching Skills Level of University Students Majoring in Physical Education in China
Study type: INTERVENTIONAL
Overall status: ENROLLING_BY_INVITATION
Phase: NA
Conditions: Teaching Skills
Keywords: Microteaching
Teaching Skills
Lead sponsor: Universiti Putra Malaysia
Sponsor class: OTHER
First posted: 2023-10-04
Enrollment: 60
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The general objective of this study is to evaluate the effect of 12-week microteaching training on the teaching skills level of university students majoring in physical education in China.

The specific objective of this study is to examine the effect of microteaching training on verbal command, movement explanation, movement demonstration, diagnostic error correction, and organization and management skills of university students majoring in physical education in China.

The participants will be divided into an experimental group and a control group. Microteaching and conventional training were used respectively to verify the influence of microteaching training on the teaching skills level of university students majoring in physical education in China.


Eligibility criteria: Inclusion Criteria:

1. University student
2. Major in Physical Education
3. Healthy
4. Able to perform all tests
5. Understand the study purposes and procedures
6. No previous experience performing microteaching training

Exclusion Criteria:

1. University students not majoring in Physical Education
2. Exclude participants who have not finished all tests
3. Not understanding the study purposes and procedures
4. Participants with an experience in microteaching

Primary outcomes:
measure: Verbal command Skill Microtraining Evaluation Form
timeFrame: Two weeks.
measure: Movement Explanation Skill Microtraining Evaluation Form
timeFrame: Two weeks.
measure: Movement Demonstration Skill Microtraining Evaluation Form
timeFrame: Two weeks.
measure: Diagnostic error correction Skill Microtraining Evaluation Form
timeFrame: Two weeks.
measure: Organization and Management Skill Microtraining Evaluation Form
timeFrame: Two weeks.
Secondary outcomes:
Other outcomes:
Locations:
city: Yancheng
country: China
facility: Yancheng Teachers University
state: Jiangsu
Study officials:
References:
Clinical trial NCT03040882: Cotton Sock in Pediatric Patients With Leg-foot Splint
Official title: Effectiveness of Cotton Sock in Pediatric Patients With Leg-foot Splint After Surgery for Correction of the Foot, in Reducing the Incidence of Cutaneous Lesions. Randomized Controlled Trial.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Flat Foot
Lead sponsor: Istituto Ortopedico Rizzoli
Sponsor class: OTHER
First posted: 2017-02-02
Enrollment: 100
Sex: ALL
Minimum age (years): 4
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The post-operative treatment of pediatric patients operated for the correction of flat foot, sees today the use of preformed leg-foot splint (Walker) as an alternative to the application of plaster casts. The change of the immobilization system has led to the appearance of problems of tolerability in particular in the skin. The problems persist also after placing a polyurethane foam dress at the heel in the immediate postoperative period. The aim of this study is to evaluate the effectiveness of a cotton sock applied inside the leg-foot splint in children operated vs the Elastic Compression Wraps in reducing the incidence of cutaneous lesions.


Eligibility criteria: Inclusion Criteria:

* Children aged \> 3 years
* Treated for flat foot
* Children with intact skin at the heel

Exclusion Criteria:

* Caregivers who cannot speak Italian
* Those who refuse to give their consent to take part in the study
* Patients with lower limb casts

Primary outcomes:
measure: Heel Pressure Sores
timeFrame: every day until discharge (expected average of 3 days).
Secondary outcomes:
measure: Pain
timeFrame: up to the first 3 days post intervention
Other outcomes:
Locations:
city: Bologna
country: Italy
facility: Istituto Ortopedico Rizzoli
Study officials:
affiliation: Istituto Ortopedico Rizzoli
name: Caterina Guerra, RN
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04005482: Blood Pressure During Rate Control in Patients With Tachycardic Atrial Fibrillation at the Emergency Department
Official title: Blood Pressure During Rate Control in Patients With Tachycardic Atrial Fibrillation at the Emergency Department
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Atrial Fibrillation
Lead sponsor: Medical University of Vienna
Sponsor class: OTHER
First posted: 2019-07-02
Enrollment: 140
Sex: ALL
Minimum age (years): 18
Maximum age (years): 120
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: We plan to include all patients admitted to the Emergency Department of the Medical University Vienna with tachycardic AF receiving rate control therapy.

Brief summary: The aim of this study is to analyse blood pressure during rate control therapy in patients with tachycardic atrial fibrillation in a real-world emergency cohort.

Detailed description: Atrial fibrillation (AF) is the primary clinical problem in 3.3% to 10.0 % emergency department (ED) admissions. Rate control is an integral part of the management of symptomatic tachycardic AF patients.

According to the recent guidelines beta-blockers, digoxin, the calcium channel blockers diltiazem and verapamil, amiodarone or combination therapy should be considered for rate control. Haemodynamic side-effects in particular hypotension may occur. Heart rate and blood pressure behavior in an ED population during rate control therapy in patients with tachycardic atrial fibrillation will be analysed.

Eligibility criteria: Inclusion Criteria:

* Age \> 18 years
* Atrial fibrillation or atrial flutter and heart rate ≥ 110 bpm
* Indication for rate control
* Informed consent

Exclusion Criteria:

• Inclusion criteria not met

Primary outcomes:
measure: Mean and maximum blood pressure difference between before (baseline) and during/after medication.
timeFrame: 20th July 2019 to 20th July 2021
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Emergency Department, Medical University Vienna
name: Hans Domanovits, Prof.
role: STUDY_DIRECTOR
References:
Clinical trial NCT00812682: Physician and Patient Perception of Adjustable Maintenance Dosing of Symbicort Turbuhaler
Official title: Physician and Patient Perception of Adjustable Maintenance Dosing of Symbicort Turbuhaler
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Perception of Physicians & Patients of AMD
Keywords: SYMBICORT AMD
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2008-12-22
Enrollment: 217
Sex: ALL
Minimum age (years): 12
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Primary Care

Brief summary: This study will evaluate the perception of the physicians and the patients about the approved adjustable dosing of Symbicort® 160/4,5. Symbicort maintenance dose will be adjusted up and down within the approved dose range of 1x2 - 4x2 inhalations per day, to the level of asthma symptoms. Patients and physicians perception of this new dosing schedule will be evaluated by means of questionnaires completion and direct questioning.


Eligibility criteria: Inclusion Criteria:

* Minimum of 6 months history of asthma and treatment with an inhaled corticosteroids for at least 3 months prior to visit 1 and/or a history of short term variation in airway function and asthma symptoms responding promptly to convent
* Patients where use of a combination (inhaled corticosteroid and long acting beta2-agonist is appropriate, i.e. not controlled on inhaled corticosteroids alone).

Exclusion Criteria:

* Asthma exacerbation requiring oral corticosteroid treatment in the four weeks prior to visit 1
* Upper Respiratory Tract Infection in the previous four weeks
* Severe cardiovascular disease or other significant concomitant disease, which may interfere with the conduct of the study.
* Women enrolled in the trial should not be planning pregnancy and should be taking adequate contraceptive measures where appropriate.
* Previous enrollment in a clinical study
* Known or suspected hypersensitivity to budesonide, formoterol or inhaled lactose

Primary outcomes:
measure: Patient satisfaction with the adjustable maintenance dosing schedule
timeFrame: Throughout the study
measure: Physicians' satisfaction with the adjustable maintenance dosing schedule
timeFrame: Throughout the study
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Medical & Regulatory Affairs Director, AstraZeneca Greece: 4
name: Panagiotis Pontikis, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT05040282: The Amenorrhea With Etonogestrel Implant
Official title: The Rate and Predictors of Amenorrhea at 1-year Follow-up in Women Using Etonogestrel Implant
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Contraception
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2021-09-10
Enrollment: 300
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: The etonogestrel subdermal implant has been available worldwide for more than 15 years. The action of etonogestrel subdermal implant is principal via suppression of ovulation, but it also has effects on cervical mucus and in some women induces suppression of endometrial proliferation. Several studies have confirmed its high efficacy and convenience. The uterine bleeding problems and in particular irregular bleeding and amenorrhea are major side effects of etonogestrel subdermal implant. A considerable number of patients request early removal due to bleeding changes. Amenorrhea occurs in about 22% in etonogestrel subdermal implant users. Despite the presence of many studies that reported the prevalence of etonogestrel subdermal implant-associated bleeding, little is known about the predictive factors affecting menstrual bleeding patterns especially amenorrhea after etonogestrel subdermal implant insertion. These predictive factors should be provided prior to the etonogestrel subdermal implant insertion which may improve acceptance and continuation of etonogestrel subdermal implant.


Eligibility criteria: Inclusion Criteria:

1. Women aged between 18 and 40 years.
2. Women who are not lactating.
3. Non-pregnant women
4. Women have regular menstrual cycles every 21-35 days with a typical cycle length variation of no more than 5 days.
5. Women who will ESI only for pregnancy prevention for at least 12 months.
6. Have not any medical or gynecologic problems.

Exclusion Criteria:

1. Women with any contraindications for progesterone-only contraception in accordance with WHO eligibility criteria.
2. Refuse participation in the study.

Primary outcomes:
measure: Number of women with amenorrhea after using etonogestrel subdermal implant
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Assiut
country: Egypt
facility: Women Health Hospital - Assiut university
Study officials:
References:
Clinical trial NCT05230082: Acupuncture in Myasthenia Gravis (AcuMG)
Official title: Acupuncture Treatment for Individuals With Myasthenia Gravis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Myasthenia Gravis
Lead sponsor: HealthPartners Institute
Sponsor class: OTHER
First posted: 2022-02-08
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to determine the effect acupuncture treatment on individuals with a diagnosis of Myasthenia Gravis (MG). A total of 20 people with MG will be enrolled in this study to receive acupuncture treatment 2 times a week for 12 weeks. Participants will be randomized into two groups: 1) Immediate start and 2) Delayed start (12 weeks). The delayed start group will act as a control group for the first 12 weeks, but then receive acupuncture treatment for 12 weeks. It is hypothesized that patients with MG who receive acupuncture treatment will have improved quality of life and activities of daily living compared to no treatment.


Eligibility criteria: Inclusion Criteria:

* Ability to provide and provision of signed and dated informed consent form
* Age 18-80
* Diagnosis of MG

Exclusion Criteria:

* Non-English speaking
* Participation in acupuncture treatment outside of the study, while enrolled
* History of any other serious neurological, psychiatric, chronic pain disorders, or seizures
* History of bleeding diathesis, other bleeding disorders, or syncope with needle puncture
* History of cardiac arrhythmia or current pacemaker, neurostimulator, or other implanted stimulation device
* Recent or active substance use disorder
* Women who are currently pregnant, lactating, or planning to become pregnant during the study
* Any other medical conditions that could affect their ability to participate in acupuncture treatments for the study duration (as determined by study investigators)
* Active participation or past participation ≤3 months in any other interventional study.
* Unwilling to participate in all study related activities

Primary outcomes:
measure: To determine the effect of acupuncture on quality of life in patients with MG
timeFrame: pre/post - 12 weeks
Secondary outcomes:
measure: To determine the effect of acupuncture on activities of daily living in patients with MG
timeFrame: pre/post - 12 weeks
Other outcomes:
Locations:
city: Saint Paul
country: United States
facility: HealthPartners Neuroscience Center
state: Minnesota
Study officials:
affiliation: HealthPartners Neuroscience Research
name: Amanda A Herrmann, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: HealthPartners Neurology
name: Gaurav K Guliani, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04546282: Resistance to Oral Therapy in Lung Cancer
Official title: Mechanisms of Resistance to 3rd Generation Thyrosine Kinase Inhibitors in Lung Cancer
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Non Small Cell Lung Cancer
Keywords: 3rd Tyrosine kinase inhibitor
Cell free DNA
Mutations
Lead sponsor: University Hospital, Montpellier
Sponsor class: OTHER
First posted: 2020-09-14
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with metastatic adenocarcinoma

Brief summary: In the management of non-small cell lung cancer of the adenocarcinoma type, different therapeutic strategies can be proposed. These strategies are defined according to the results of a biological analysis of blood and/or tissue samples from the lung tumor. Mutations in the tumor DNA are sought. Thus, patients with sensitizing mutations can benefit from a treatment with a 3rd generation tyroine kinase inhibitor (TKI) whose efficacy has been widely demonstrated. Patients without tumor mutations will not benefit. However, resistance to TKIs appears after a certain time, often linked to the appearance of new mutations in the tumor. For this reason, blood biologic analyses are regularly performed to search for the emergence of resistance mutations and to propose a therapeutic alternative as soon as possible.

These analyses are performed routinely in the laboratory. In the course of these analyses, the investigators have identified conventional mutations but also new mutations not previously described in the literature.

Our objective is to list all the molecular abnormalities revealed during blood biological analyses, to determine their frequency and to study whether certain abnormalities can be linked to resistance to TKI.


Eligibility criteria: Inclusion Criteria:

* advanced non-small cell lung cancer stage IIIB/IV
* Documentation of activating EGFR mutations (exon 19 deletions or exon 21 L858R substitution mutations) at the time of initial diagnosis
* Patient may receive up to one line of third EGFR TKI
* Plasma sample testing performed to detect EGFR TKI resistance

Exclusion Criteria:

* Patients have other concurrent cancers
* Patients who are not eligible receive TKI

Primary outcomes:
measure: Description of the molecular alterations detected in patients treated with 3rd TKI and assessment link with progression free survival and overall survival features.
timeFrame: The analysis of the TKI effectiveness and the appearance of mutations will be performed over a period of 24 months.
Secondary outcomes:
measure: Frequency of detected molecular alterations
timeFrame: The analysis of the TKI effectiveness and the appearance of mutations will be performed over a period of 24 months.
Other outcomes:
Locations:
city: Montpellier
country: France
facility: University Hospital
state: Hérault
Study officials:
affiliation: UH Montpellier
name: Jerome Solassol
role: STUDY_DIRECTOR
References:
Clinical trial NCT02047682: Implementation of Physical Exercise at the Workplace (IRMA10) - Occupational Load
Official title: Implementation of Physical Exercise at the Workplace (IRMA10) - Occupational Load
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Musculoskeletal Disorders
Stress
Lead sponsor: National Research Centre for the Working Environment, Denmark
Sponsor class: OTHER_GOV
Collaborators: name: University of Southampton
First posted: 2014-01-28
Enrollment: 36
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 67
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: Static postures, repetitive work tasks, and work stress increase the risk for musculoskeletal disorders and sickness absence. Objective measurements of occupational loadings - EMG for muscular activity, EEG for cognitive activity, ECG for cardiovascular activity and heart rate variability, actigraphy for bodily movements - may provide useful early indicators of muscular, cognitive and cardiovascular overload.

The aim of this study is to investigate the effect of an individually tailored bio-psycho-social intervention strategy versus "usual care" ergonomics and standard physical exercises (reference group) on these risk factors in lab technicians with a history of work-related musculoskeletal pain.


Eligibility criteria: Inclusion Criteria:

* Laboratory technician
* Pain intensity \>= 3 (scale of 0-10)
* Pain duration \>= 3 months
* Pain frequency \>= 3 days per week

Exclusion Criteria:

* life threatening disease
* pregnancy

Primary outcomes:
measure: EMG gaps
timeFrame: change from baseline to week 10
Secondary outcomes:
measure: EEG
timeFrame: change from baseline to week 10
measure: HRV
timeFrame: change from baseline til 10 week followup
Other outcomes:
Locations:
city: Copenhagen
country: Denmark
facility: National Research Centre for the Working Environment
Study officials:
affiliation: National Research Centre for the Working Environment, Denmark
name: Lars L Andersen, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02509182: The Effect of Decreasing the Inspired Oxygen Concentration on Post-Operative Oxygenation After Primary Lobectomy
Official title: The Effect of Decreasing the Inspired Oxygen Concentration on Post-Operative Oxygenation After Primary Lobectomy: A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE4
Conditions: Hyperoxia
Keywords: Hyperoxia
One-Lung Ventilation
Thoracic Surgery
Anesthesiology
Lead sponsor: Yale University
Sponsor class: OTHER
First posted: 2015-07-27
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to test the hypothesis that decreasing the inspired oxygen concentration during thoracic surgery requiring one lung ventilation will improve post-operative oxygenation.

Detailed description: One lung ventilation is frequently required during thoracic surgery and results in decreased lung function post-operatively. Supra-physiologic oxygen levels during surgery may contribute to this decrease in lung function by worsening lung injury intra-operatively.

This study will include patients undergoing surgery to remove a lung lobe requiring one lung ventilation.

The patients will be divided into two groups with the experimental group receiving a 60% oxygen in air mixture and the control group receiving 100% oxygen.

The two groups will be compared by using a measure of lung function (the ratio of the partial pressure of oxygen in arterial blood to the inspired oxygen concentration) and blood levels of a protein correlated with lung injury (receptor of advanced glycation end products RAGE).

Eligibility criteria: Inclusion Criteria:

1. Adults, 18 years of age and older, male or female.
2. American Society of Anesthesiology (ASA) physical status I, II, III or IV
3. Subjects who are scheduled for elective primary pulmonary lobectomy.
4. Subjects who have an arterial line placed as part of routine anesthetic management
5. Subjects who can understand and communicate in English.

Exclusion Criteria:

1. Subjects with a history of difficult intubation
2. Subjects with a high risk of aspiration during induction of anesthesia
3. Subjects with morbid obesity (BMI greater than or equal to 40)
4. Subjects with unable to provide consent
5. Subjects who are minors
6. Subjects who are not English speaking

Primary outcomes:
measure: PaO2 to FiO2 ratio
timeFrame: Post-operative day 1
Secondary outcomes:
measure: Mortality
timeFrame: 30 days
measure: Mortality
timeFrame: 1 year
measure: Hypoxemia less than 90%
timeFrame: Intra-operative
measure: Blood level of receptor of advanced glycation end-products (RAGE) protein
timeFrame: Post-operative day 1
Other outcomes:
Locations:
city: New Haven
country: United States
facility: Yale New Haven Hospital
state: Connecticut
Study officials:
affiliation: Yale University
name: Wanda Popescu, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Yale University
name: Nathan Clendenen, MD,MS
role: PRINCIPAL_INVESTIGATOR
References: